The Pharmacy Times® Hematology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of blood disorders, include blood and bone marrow cancers, anemia, hemophilia, blood-clotting disorders, and leukemia.
November 21st 2024
Rusfertide may sustain hematocrit levels in patients with polycythemia vera.
Optimizing Use of Small Molecule Inhibitors in Chronic Lymphocytic Leukemia: Strategies for Safe and Effective...
1.0 Credits / Hematology, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Management of DOAC-Associated Bleeding With Reversal Agents: A Comprehensive Approach for Health-System Pharma...
1.0 Credit / Hematology
View More
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodi...
1.5 Credits / Oncology, Hematology, Hematologic Cancer
View More
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Manage...
1.5 Credits / Hematology, Hematologic Cancer, Oncology
View More
The Role of the Pharmacist in Paroxysmal Nocturnal Hemoglobinuria Management
1.0 Credit / Hematology
View More
Overview of Paroxysmal Nocturnal Hemoglobinuria: Pathophysiology of the Complement Pathway and Clinical and Ec...
1.0 Credit / Hematology
View More
Clinical Updates in the Management of Paroxysmal Nocturnal Hemoglobinuria With Patient Perspectives
1.0 Credit / Hematology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Overcoming Disparities in Multiple Myeloma Treatment: Empowering Pharmacists to Drive Change
1.0 Credit / Health Equity, Diversity & Inclusion, Hematologic Cancer, Hematology, Oncology
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Combating Advancing Cancers With CAR T-Cell Therapy
Immunotherapy methods emerged on the oncology market as adoptive cell transfers, specifically chimeric antigen receptor (CAR) T-cell therapies, with clear benefits in hematologic malignancy treatment.
Read More
DAURISMO for Acute Myeloid Leukemia
September 5th 2019On November 2018, the FDA approved Pfizer’s glasdegib (Daurismo) for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 75 years and older with comorbidities that prevent the use of intensive induction-dose chemotherapy.
Read More